Evidence map›Paper›PMID 35372992›Full record

Trial reportKidney3602021

Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.

Patrick B Mark, Pardeep S Jhund, Matthew R Walters, Mark C Petrie, Albert Power, Claire White, Michele Robertson, Eugene Connolly, Stefan D Anker, Sunil Bhandari and 9 more

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Kidney360, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 2 countries.

Patrick B MarkInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-3387-2123
Pardeep S JhundInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-4306-5317
Matthew R WaltersInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Mark C PetrieInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-6333-9496
Albert PowerRichard Bright Renal Unit, North Bristol NHS Trust, Bristol, United Kingdom.
Claire WhiteDepartment of Renal Medicine, King's College Hospital, London, United Kingdom.
Michele RobertsonRobertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.
Eugene ConnollyInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Stefan D AnkerHull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, Hull, United Kingdom.
Sunil BhandariDepartment of Cardiology, Berlin-Brandenburg Center for Regenerative Therapies, German Center for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-0996-9622
Kenneth FarringtonLister Hospital, Stevenage, United Kingdom.ORCID 0000-0001-8862-6056
Philip A KalraSalford Royal Hospital and University of Manchester, Manchester, United Kingdom.
Charles R V TomsonDepartment of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, United Kingdom.ORCID 0000-0002-0224-8726
David C WheelerDepartment of Renal Medicine, University College London, London, United Kingdom.ORCID 0000-0003-0745-3478
Christopher G WinearlsOxford Kidney Unit, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
John J V McMurrayInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-6317-3975
Iain C MacdougallDepartment of Renal Medicine, King's College Hospital, London, United Kingdom.
Ian FordRobertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-5927-1823
PIVOTAL Investigators
University of Glasgow · GBKing's College Hospital · GBCharité - Universitätsmedizin Berlin · DEChurchill Hospital · GBFreeman Hospital · GBHull and East Yorkshire Hospitals NHS Trust · GBLister Hospital · GBNorth Bristol NHS Trust · GBUniversity College London · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: People with kidney failure treated with hemodialysis (HD) are at increased risk of stroke compared with similarly aged people with normal kidney function. One concern is that treatment of renal anemia might increase stroke risk. We studied risk factors for stroke in a prespecified secondary analysis of a randomized, controlled trial of intravenous iron treatment strategies in HD. Methods: We analyzed data from the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL) trial, focusing on variables associated with risk of stroke. The trial randomized 2141 adults who had started HD <12 months earlier and who were receiving an erythropoiesis-stimulating agent (ESA) to high-dose IV iron administered proactively or low-dose IV iron administered reactively in a 1:1 ratio. Possible stroke events were independently adjudicated. We performed analyses to identify variables associated with stroke during follow-up and assessed survival following stroke. Results: During a median 2.1 years of follow-up, 69 (3.2%) patients experienced a first postrandomization stroke. Fifty-seven (82.6%) were ischemic strokes, and 12 (17.4%) were hemorrhagic strokes. There were 34 postrandomization strokes in the proactive arm and 35 postrandomization strokes in the reactive arm (hazard ratio, 0.90; 95% confidence interval, 0.56 to 1.44; Conclusions: In patients on HD, stroke risk is broadly associated with risk factors previously described to increase cardiovascular risk in this population. Proactive intravenous iron does not increase stroke risk.

Indexed as

AnemiaHematinicsStrokeAdultAgedFemaleHumansIronRenal DialysisHematinicsIronadministrationanemiacardiovascular diseasedialysisheart failurehemodialysisironrandomized controlled trialsrenal dialysisstrokesurvival

Identifiers

PMID35372992
PMCPMC8785850
OpenAlexW3199004537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.